Navalign LLC Has $741,000 Stake in Boston Scientific Co. (NYSE:BSX)

Navalign LLC reduced its position in Boston Scientific Co. (NYSE:BSX) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,823 shares of the medical equipment provider’s stock after selling 292 shares during the quarter. Navalign LLC’s holdings in Boston Scientific were worth $741,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Bruce G. Allen Investments LLC bought a new stake in Boston Scientific during the fourth quarter worth about $28,000. Sunbelt Securities Inc. bought a new position in shares of Boston Scientific during the first quarter worth $32,000. Motco boosted its holdings in shares of Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 372 shares during the period. Coppell Advisory Solutions LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $34,000. Finally, Acadian Asset Management LLC acquired a new position in Boston Scientific during the first quarter valued at approximately $35,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Needham & Company LLC raised their price objective on Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Mizuho upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating and upped their target price for the stock from $65.00 to $80.00 in a report on Thursday, February 1st. Citigroup raised their price target on shares of Boston Scientific from $65.00 to $71.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Finally, Royal Bank of Canada upped their price objective on Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $66.62.

Insiders Place Their Bets

In related news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares in the company, valued at $17,883,756.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Daniel J. Brennan sold 13,662 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $66.35, for a total value of $463,322.05. Following the completion of the sale, the executive vice president now directly owns 53,788 shares in the company, valued at $3,568,833.80. The disclosure for this sale can be found here. Insiders have sold a total of 76,460 shares of company stock valued at $4,759,945 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $0.12 on Thursday, hitting $68.50. 6,533,469 shares of the company traded hands, compared to its average volume of 6,562,845. The firm’s 50-day simple moving average is $65.40 and its 200 day simple moving average is $58.12. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $68.92. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The company has a market cap of $100.69 billion, a P/E ratio of 64.02, a P/E/G ratio of 2.38 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the previous year, the business earned $0.45 earnings per share. Analysts expect that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.